RxSight (RXST) EBIAT (2020 - 2025)
Historic EBIAT for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$9.8 million.
- RxSight's EBIAT fell 5487.54% to -$9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.7 million, marking a year-over-year decrease of 1640.71%. This contributed to the annual value of -$27.5 million for FY2024, which is 4351.75% up from last year.
- According to the latest figures from Q3 2025, RxSight's EBIAT is -$9.8 million, which was down 5487.54% from -$11.8 million recorded in Q2 2025.
- RxSight's 5-year EBIAT high stood at -$5.9 million for Q4 2024, and its period low was -$17.6 million during Q1 2022.
- Its 5-year average for EBIAT is -$11.6 million, with a median of -$12.4 million in 2023.
- Per our database at Business Quant, RxSight's EBIAT tumbled by 15983.65% in 2021 and then soared by 5596.2% in 2024.
- Over the past 5 years, RxSight's EBIAT (Quarter) stood at -$15.7 million in 2021, then grew by 0.79% to -$15.6 million in 2022, then soared by 41.21% to -$9.2 million in 2023, then surged by 35.29% to -$5.9 million in 2024, then crashed by 65.31% to -$9.8 million in 2025.
- Its EBIAT stands at -$9.8 million for Q3 2025, versus -$11.8 million for Q2 2025 and -$8.2 million for Q1 2025.